2026-2034年全球霍乱疫苗市场规模、份额、趋势和成长分析报告

霍乱疫苗市场预计将从 2025 年的 1.1036 亿美元成长到 2034 年的 2.762 亿美元，2026 年至 2034 年的复合年增长率为 10.73%。

随着公共卫生部门将疾病控制和提高全球疫苗接种率列为优先事项，霍乱疫苗市场也不断发展。未来的疫苗可望利用新型口服製剂、耐热递送系统和优化的佐剂，以提高免疫抗原性、延长保质期并便于在偏远地区部署。与数位化免疫追踪平台的整合将有助于有效监测疫苗接种率和控制疫情爆发。

重组载体疫苗和合成胜肽製剂等新兴技术可望缩短生产週期并扩大株覆盖范围。人工智慧驱动的流行病学模型指导策略性疫苗宣传活动，优化资源分配并降低疾病发生率。行动医疗系统透过提高疫苗认知度、优化疫苗接种计画管理以及追踪本地接种依从性，为公共卫生基础设施提供支援。

未来的成长将得益于旨在预防水传播感染疾病、改善供应链物流和支持大规模免疫政策的国际措施。透过结合创新疫苗技术、数位健康整合和积极主动的疫情管理，霍乱疫苗将在减轻全球疾病负担和增强公共卫生韧性方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球霍乱疫苗市场：按类型划分

• 市场分析、洞察与预测
• 重组B次单元全细胞霍乱弧菌O1型疫苗
• 灭活口服氧
• O139

第五章 全球霍乱疫苗市场：依产品划分

• 市场分析、洞察与预测
• Vaxchora
• 杜科拉尔
• 尚科尔
• 其他的

第六章 全球霍乱疫苗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他的

第七章 全球霍乱疫苗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Valneva SE
  • Sanofi SA
  • Emergent BioSolutions Inc
  • PaxVax Inc
  • EuBiologics Co.Ltd
  • Shantha Biotechnics Limited
  • Hilleman Laboratories
  • Astellas Pharma Inc
  • Incepta Vaccine Ltd
  • Vabiotech

The Cholera Vaccines Market size is expected to reach USD 276.20 Million in 2034 from USD 110.36 Million (2025) growing at a CAGR of 10.73% during 2026-2034.

The cholera vaccines market is advancing as public health authorities prioritize epidemic preparedness and global immunization coverage. Future vaccines will leverage novel oral formulations, thermostable delivery systems, and adjuvant optimization to improve immunogenicity, shelf life, and ease of deployment in remote regions. Integration with digital immunization tracking platforms will enable efficient monitoring of coverage rates and outbreak management.

Emerging technologies, including recombinant vector vaccines and synthetic peptide-based formulations, promise faster production timelines and broader strain coverage. AI-driven epidemiological modeling will guide strategic vaccination campaigns, optimizing resource allocation and reducing disease incidence. Mobile health systems will facilitate community-level vaccine awareness, scheduling, and adherence tracking, supporting public health infrastructure.

Future growth will be fueled by global initiatives targeting waterborne disease prevention, improved supply chain logistics, and policy support for mass vaccination. By combining innovative vaccine technologies, digital health integration, and proactive outbreak management, cholera vaccines will play a critical role in reducing global disease burden and strengthening public health resilience.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Whole Cell v. Cholerae O1 with Recombinant B- subunit
• Killed Oral O1
• O139

By Product

• Vaxchora
• Dukoral
• Shanchol
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

COMPANIES PROFILED

• Valneva SE, Sanofi SA, Emergent BioSolutions Inc, PaxVax Inc, EuBiologics Co, Ltd, Shantha Biotechnics Limited, Hilleman Laboratories, Astellas Pharma Inc, Incepta Vaccine Ltd, Vabiotech
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHOLERA VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Whole Cell v. Cholerae O1 with Recombinant B- subunit Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Killed Oral O1 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. O139 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL CHOLERA VACCINES MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Vaxchora Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Dukoral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Shanchol Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL CHOLERA VACCINES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL CHOLERA VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Product
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Product
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Product
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Product
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Product
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHOLERA VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Valneva SE
  • 9.2.2 Sanofi S.A
  • 9.2.3 Emergent BioSolutions Inc
  • 9.2.4 PaxVax Inc
  • 9.2.5 EuBiologics Co.Ltd
  • 9.2.6 Shantha Biotechnics Limited
  • 9.2.7 Hilleman Laboratories
  • 9.2.8 Astellas Pharma Inc
  • 9.2.9 Incepta Vaccine Ltd
  • 9.2.10 Vabiotech